Reuters Award Finalist

This press release is suitable for all audiences.


Proveca are through to the final nominations for a Reuters award – Valuable Medical Education/Awareness Initiative Award

Proveca is delighted to be in the final nominations for a Reuters award in the Valuable Medical Education/Awareness Initiative Award category at the Reuters Events Pharma Awards EU 2024. There were over 200 submissions overall for this category, so getting this far is already a significant achievement for Proveca. Other finalists in this category are pharmaceutical companies: GSK, AstraZeneca, Boehringer Ingelheim, and Moderna.

The winners of all the categories will be announced on the keynote stage at the Reuters Pharma EU flagship event on the morning of Tuesday 16th April.

Helen Wilmshurst – Head of Marketing at Proveca

‘We are absolutely thrilled to be one of the finalists for this prestigious award. One of our company values is pioneering and the project we have submitted certainly ticks this box as it is highly educational and the mini orodispersible tablets are memorable to healthcare professionals. To date, the initiative has certainly stimulated awareness about the need for appropriate paediatric medicines and has showcased an example of a potential innovative formulation in paediatrics’. 


About Proveca

Proveca is a European pharmaceutical company who specialise in the development and licensing of medicines to address the unmet medical needs for children.

Working with clinicians, parents, carers and children, Proveca are leading the way to provide licenced medicines that are tailored to children’s specific requirements.




Created April 2024